Blood News and Research

RSS

Dieters who consumed more milk or milk products lost more weight :Study

A new weight loss study conducted by Ben-Gurion University of the Negev (BGU) researchers reveals that dieters who consumed milk or milk products lost more weight on average than those who consumed little to no milk products.

21 Sep 2010

FDA Advisory Committee recommends approval of dabigatran etexilate for stroke prevention in AFib patients

The U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee today voted 9 to 0 in favor of approving dabigatran etexilate for stroke prevention in patients with atrial fibrillation (AFib). An estimated 2.3 million Americans have AFib and the prevalence is expected to increase 2.5 fold to 5.6 million by 2050, reflecting the growing population of elderly individuals.

21 Sep 2010

Zynex to develop central blood volume monitoring device

Zynex, Inc., a provider of pain management systems and electrotherapy products for medical patients with functional disability, announces that its newly formed wholly-owned subsidiary, Zynex Monitoring Solutions Inc., is developing a device for monitoring of central blood volume for use in operating rooms, detecting blood loss during surgery and detecting internal bleeding in the recovery room.

21 Sep 2010

Opinions: MDGs

"The overarching and noble goal [of this week's Millennium Development Goal (MDG) summit in New York] is reducing global poverty. But the most compelling and achievable objectives - huge reductions in maternal and child mortality worldwide - will be severely undermined if the Obama administration either directly or covertly integrates abortion into the final outcome document," Rep. Chris Smith (R-N.J.) writes in a Washington Post opinion piece.

21 Sep 2010

Dengue fever vaccine in the pipeline

Australians researchers are moving towards producing the first ever vaccine for dengue fever, the potentially life-threatening infection spread by mosquitoes in the tropics. At present late stage clinical trials are underway for a vaccine that would protect against all four known strains of the disease. Participants are now being recruited in Perth, Adelaide and Brisbane.

20 Sep 2010

Biomarkers may help predict children at high risk of developing type 2 diabetes

Children who have a high risk of developing type 2 diabetes might be identified earlier by way of tell-tale genetic indicators known as biomarkers. Some of those new biomarkers might be pinpointed in research led by Nancy F. Butte and funded by the U.S. Department of Agriculture (USDA) and the U.S. Department of Health and Human Service's National Institutes of Health.

20 Sep 2010

Crestor suppressed human cancer cells transplanted to mice

A drug commonly prescribed for people with high cholesterol may also be effective in treating prostate cancer, according to new research by Dr. Xiao-Yan Wen at St. Michael's Hospital.

20 Sep 2010

Researchers identify protein essential for dendritic cell development

A protein called PU.1 is essential for the development of dendritic cells, the sentinels of the immune system, Walter and Eliza Hall Institute researchers in Melbourne, Australia, have shown.

20 Sep 2010

Seven abstracts on Lantheus' PET imaging candidates to be presented at ASNC2010

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that seven abstracts related to two of the company's cardiac Positron Emission Tomography (PET) imaging candidates will be presented at ASNC2010, the 15th Annual Scientific Session of the American Society of Nuclear Cardiology, being held September 23-26, 2010 in Philadelphia.

20 Sep 2010

$Neovasc commences enrollment in Reducer trial for refractory angina$

Neovasc commences enrollment in Reducer trial for refractory angina

Neovasc Inc., a developer of novel technologies used to treat vascular disease, today announced that the first patients have been enrolled in its COSIRA trial designed to assess the clinical efficacy of the Neovasc Reducer(TM) product for the treatment of refractory angina. The COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) trial is a multicenter, sham-controlled, randomized, double-blinded study of the Reducer that is expected to enroll up to 124 patients.

20 Sep 2010

Chronix Biomedical completes Series E financing

Chronix Biomedical today announced that it has completed a Series E financing that raised $1.8 million from existing and new investors. Chronix is developing disease-specific biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells. Chronix's serum DNA biomarkers are applicable to a wide range of cancers and other chronic diseases.

20 Sep 2010

Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients

Bristol-Myers Squibb Company and AstraZeneca today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride (sulphonylurea) therapy produced significant reductions in glycosylated hemoglobin levels (HbA1c) in adult patients with type 2 diabetes compared to glimepiride alone.

20 Sep 2010

MultiStem multipotent adult progenitor cell therapy preserves 'blood brain barrier'

Athersys, Inc. announced today the publication of a key study in the October issue of Experimental Neurology conducted by researchers at Athersys, the University of Texas Medical School, the Michael E. DeBakey Institute for Comparative Cardiovascular Science and Biomedical Devices, and Texas A&M University.

20 Sep 2010

Sanofi-aventis releases Lantus(R) study results for type 2 diabetes

Sanofi-aventis announced today results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.

20 Sep 2010

Chelsea Therapeutics' Phase III NORTHERA Study 301 meets primary endpoint

Chelsea Therapeutics International, Ltd. announced that preliminary analyses of its Phase III NORTHERA™ Study 301 met its primary endpoint. Treatment with Northera provided clinically meaningful and statistically significant improvement.

20 Sep 2010

Cord Blood America acquires controlling interest of Biocordcell Argentina

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced that it has purchased controlling interest, 50.1 percent, of Biocordcell Argentina S.A. (BioCells, Inc.).

20 Sep 2010

Lisofylline drug effective for Type 2 diabetes

Australian scientists, in association with US pharmaceutical company DiaKine Therapeutics, have shown that a drug candidate, Lisofylline, could be useful in treating Type 2 diabetes.

20 Sep 2010

URB937 drug boosts natural painkiller level: Study

A new study has shown how a novel compound boosts levels of a natural painkiller at the site of an injury. The ground-breaking study published today in Nature Neuroscience shows how the potential drug URB937 acts in peripheral tissue and may have the potential to relieve pain without the side effects associated with many current painkillers that act centrally on the nervous system.

20 Sep 2010

New law brings changes to health insurance rules this week

A variety of consumer friendly health reform rules will go into effect this week, promising to make life easier for young adults, parents, children with preexisting conditions, people with chronic diseases, and people appealing claims that have been denied. Starting Thursday, insurance companies must allow young adults to remain on their parents' plans until age 26, with some conditions.

20 Sep 2010

Tiotropium bromide shows potential as an alternative asthma treatment

A drug commonly used for the treatment of chronic obstructive pulmonary disease (COPD) successfully treats adults whose asthma is not well-controlled on low doses of inhaled corticosteroids, reported researchers supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.

20 Sep 2010